JAKARTA, investor.id – Molnupiravir has been discussed recently because it is believed to be a powerful Covid-19 drug.
Spokesperson for Covid-19 Vaccination of the Ministry of Health (Kemkes), Dr. Siti Nadia Tarmizi said, molnupiravir as a Covid-19 drug is still waiting for the results of clinical trials and parallel publication by the Food and Drug Administration (BPOM).
“We are waiting for the completion of clinical trials and parallel publications,” he said when contacted Beritasatu.com, Sunday (10/10/2021).
Nadia said, BPOM can also review for the possibility of providing emergency use or Emergency Use Authorization (USA).
Previously, the Coordinator of the Expert Team and Government Spokesperson for Handling Covid-19, Wiku Adisasmito, said that Molnupiravir, which is currently being discussed because it is believed to be a powerful Covid-19 drug, still has to go through the testing stages that have been determined by BPOM if it is to be used in Indonesia.
The stages in question, said Wiku, are starting from discovery and development to monitoring the consumption of drugs in the community so that they are safe when used by the Indonesian people.
“Before it can be used in Indonesia, of course, the drug Molnupiravir must first undergo the stages required by BPOM, starting from the discovery and development stage to monitoring the safety of drug consumption in the community,” Wiku said in a virtual press conference “Development of Handling Covid-19 in Indonesia”, Thursday (7/10/2021).
Wiku said Molnupiravir is one of the antivirals, which was originally developed for influenza, but was later thought to be effective in treating and treating the Covid-19 virus.
“This drug works by triggering an error in the process of multiplying the virus in the body,” he said.
Currently, the drug Molnupiravir, made by a pharmaceutical company from the United States, is in the process of applying for a permit to the Food and Drug Administration (FDA) as the Food and Drug Supervisory Agency in the United States (US).
Wiku said that the Indonesian government is committed to continuing to improve the accessibility of vaccines and drugs to all levels of society. The Indonesian government also opens opportunities for researchers to innovate to find safe and effective Covid-19 vaccines and drugs.
“However, innovations carried out must comply with national and international standards and comply with all stages of developing standard vaccines and drugs, solely so that their safety and effectiveness are guaranteed,” he said.
Innovations carried out must comply with national and international standards and comply with all stages of developing standardized vaccines and drugs solely so that their safety and effectiveness are guaranteed.
“Prevention efforts through 3M and vaccines as well as handling Covid-19 with drugs and therapies are equally important and complementary,” concluded Wiku.
Editor : Mount Kunjana ([email protected])
